You are leaving our website

You have clicked on a link that will take you to a third-party website that Alliance Pharmaceuticals plc group (“Alliance”) is not responsible for.

Please read the following disclaimer and click “I agree” to proceed to the third-party website.

By clicking to continue you agree that:You are leaving Alliance`s website.


  • Is not responsible for the content or accuracy of the third-party website nor endorse or guarantee any services or information they may offer.
  • Does not represent either the third-party website or you (the visitor) if you enter into an agreement or transaction.
  • Privacy and security policies do not apply to third-party websites.
or Decline

At a glance

Our 2020 Financial Highlights

Strong performance from Consumer Healthcare brands, which now account for over two-thirds of Group see-through revenues*

137.5 £m See-through Revenue*
33.5 £m Underlying Profit Before Tax
5.11p Underlying Basic EPS
129.8 £m Statutory Revenue
13.0 £m Reported Profit Before Tax

*Non-IFRS alternative performance measures. See-through revenue includes sales from Nizoral as if they had been invoiced by Alliance. For statutory accounting purposes the product margin on Nizoral sales is included within Revenue, in line with IFRS 15.

Results centre

2020 Annual Report

Annual Report

2020 Annual Report (6.2mb)


Working together to acheive more for investors

Our alliances, clear strategy and proven business model enable us to deliver consistent and sustained returns for investors.

Why Invest

2020 Preliminary Results Presentation

Continued strong performance, despite pandemic challenges


Financial calendar

20Jul 2021 Trading Update 2021


Results centre